Venclexta (Venetoclax): Uses, Dosage, Side Effects & More

Venclexta (venetoclax) is a targeted therapy designed to help manage specific types of cancer by addressing the underlying biology of cancer cells. This guide provides an overview of how Venclexta works, what to expect during treatment, and how to stay informed as you work with your doctor to achieve the best possible outcomes.

Venclexta is an oral tablet taken daily with a meal. Treatment begins with a “ramp-up” phase to gradually increase the dosage over a few days or weeks, depending on the specific treatment plan. One of the most significant risks is tumor lysis syndrome (TLS), which requires strict hydration and frequent blood work during the initial weeks of treatment.

What is Venclexta used for?

Venclexta is a prescription tablet containing the active ingredient venetoclax. It belongs to a drug class called B-cell lymphoma-2 (BCL-2) inhibitors. Unlike traditional chemotherapy, which attacks all rapidly dividing cells throughout the body, Venclexta is a targeted therapy. It works by specifically targeting a protein that helps cancer cells survive.

Approved uses

Venclexta is used in adults to treat:

• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): In these conditions, the body produces too many abnormal lymphocytes. Venclexta can be used as a primary treatment or after other therapies have been tried, often in combination with a BTK inhibitor.
• Acute myeloid leukemia (AML): For newly diagnosed AML, it is used in combination with chemotherapy medications like azacitidine, decitabine, or low dose cytarabine. This combination is commonly prescribed for adults aged 75 or older or those with other health conditions that would make intensive, high-dose chemotherapy too physically demanding.

How does Venclexta work?

Venclexta works by addressing the specific biological processes that allow cancer cells to survive longer than they should. In many blood cancers, cells produce excessive amounts of the BCL-2 protein. This protein plays a key role in regulating cell life cycles by blocking apoptosis (natural, programmed cell death). When BCL-2 levels are too high, cancer cells continue to live and multiply when they otherwise would have died. This leads to a buildup of cancer cells in the blood and bone marrow, which eventually crowds out healthy blood cells.

Venclexta is designed to bind directly to the BCL-2 protein and stop it from working. By blocking this protein, Venclexta allows the natural process of cell death to resume, leading to the death and clearance of cancer cells from the body. This process helps restore the balance of cells in the bone marrow, potentially allowing for the return of typical, healthy blood cell production.

Potential side effects of Venclexta

While Venclexta is a targeted therapy, it can still affect healthy cells and cause side effects. Most side effects are manageable with the help of your healthcare team.

Common side effects

In clinical trials, many people reported mild to moderate symptoms as their bodies adjusted to the therapy. These side effects include:

• Digestive problems, such as nausea, diarrhea, or upset stomach
• Fatigue
• Low white blood cell count (leukopenia), which can increase the risk of infection

Serious side effects

• Tumor lysis syndrome (TLS): TLS is most common at the start of treatment, when a large number of cancer cells rapidly die off. When this happens, these cells release uric acid, potassium, phosphorus, and changes in calcium levels into the blood. If these levels rise too fast, they can overwhelm the kidneys, potentially leading to kidney failure or dangerous heart rhythm problems.
• Serious infections: Because the drug can lower white blood cell counts significantly, there may be a higher risk of developing a serious infection. Serious cases of COVID-19, pneumonia, and sepsis have been reported. It is important to stay up to date on vaccinations and report any signs of fever or illness to your doctor immediately.
• Thrombocytopenia (low platelet count): Platelets help your blood clot. If your platelet count is too low, you may notice that you bruise more easily or that minor cuts take longer to stop bleeding.
• Secondary cancers: In clinical studies, a small number of people developed a different type of cancer (such as skin cancer) during treatment. It’s important to contact a doctor right away if you experience symptoms of a severe side effect, such as sudden confusion, unusually dark or “tea-colored” urine, heart palpitations, severe nausea, or seizure. For a medical emergency, contact emergency services.

Venclexta’s dosage and ramp-up phase

Venclexta is available as an oral tablet in three strengths: 10 milligrams (mg), 50 mg, and 100 mg. Because it can rapidly break down cancer cells, doctors introduce Venclexta slowly to prevent the risk of side effects. This slow dosage increase is commonly called the “ramp-up phase.”

• For CLL and SLL: The typical ramp-up phase lasts about 5 weeks. Doctors will typically start on a very low dose (usually 20 mg), which increases weekly as the body adjusts to treatment. The standard daily maintenance dose is 400 mg.
• For AML: The ramp-up phase for AML treatment is much shorter, typically occurring over the first 3 to 4 days of the first treatment cycle. The recommended dosage of Venclexta for AML is either 400 mg or 600 mg, depending on which other medication is being received.

Side effect monitoring during ramp-up

Because the risk of cells breaking down too quickly is highest at the beginning, close monitoring is essential. Blood tests are performed before the first dose and before every dose increase. In many cases, these labs must be checked as early as 6 to 8 hours after taking the dose to ensure creatinine and electrolyte levels are stable.

Interactions and precautions

Because Venclexta is processed by specific enzymes in the liver (specifically CYP3A), other substances that use those same enzymes can affect how well Venclexta works.

Drug and food interactions

• Strong CYP3A inhibitors: Certain antifungals (like ketoconazole), specific antibiotics (like clarithromycin), and some HIV medications can interfere with Venclexta. Dose adjustments or alternative supporting medications may be necessary.
• Dietary restrictions: Certain fruits can block the enzymes that break down Venclexta. It’s important to avoid eating grapefruit, starfruit, and Seville oranges throughout treatment.
• Warfarin and digoxin: Venclexta can increase the levels of warfarin and digoxin in the body. In turn, this can increase the risk of serious side effects, such as excessive bleeding. Taking these medications at least 6 hours before Venclexta may be advised to prevent an interaction.
• Live vaccines: It’s important that live vaccines are not received just before, during, or after treatment with Venclexta until a doctor confirms it is safe. Because Venclexta can weaken the immune system, a live vaccine may not work as well or could potentially cause a serious infection.

Health conditions and fertility

• Organ function: For a serious liver condition (specifically defined as a “C” on the Child-Pugh score), a lower dose is likely prescribed, with closer kidney function monitoring due to the risk of TLS.
• Reproductive health: Venclexta can be harmful to a developing fetus. If you or your partner can become pregnant, it’s important to use effective birth control during treatment and for 30 days after the final dose. It’s also important to avoid breastfeeding during treatment and for at least 1 week after the final dose.
• Male fertility: Animal studies suggest that Venclexta may affect male fertility. However, animal studies do not always predict how the drug will affect humans. If considering starting a family in the future, discussing fertility preservation options with a doctor before beginning treatment is recommended.

Comparing Venclexta and Imbruvica

When discussing treatment options for CLL or SLL, Venclexta may be compared with Imbruvica (ibrutinib). While both medications are highly effective targeted therapies, they offer different paths for treatment.

• Mechanism: Venclexta targets the BCL-2 protein, essentially forcing cancer cells to die. Imbruvica is a BTK inhibitor that blocks the signals cancer cells use to grow and multiply.
• Treatment duration: When used in combination with other drugs for CLL or SLL, Venclexta is often given as a “fixed-duration” therapy (for example, 12 or 24 months). However, when Venclexta or Imbruvica is used alone, either can be taken as a continuous daily pill for as long as it remains safe and effective.
• Safety monitoring: While Venclexta requires intense monitoring for TLS during the first few weeks, Imbruvica may require more long-term monitoring for heart rhythm problems (like atrial fibrillation) or high blood pressure.

Cost and savings

Venclexta is a specialized medication, and its cost can vary significantly depending on insurance providers. The manufacturer offers patient assistance programs and copay cards that can significantly reduce out-of-pocket costs. Your pharmacy or a financial counselor at your clinic can provide information on these programs.

Venclexta is an effective treatment option for CLL, SLL, and AML. While the initial “ramp-up” phase requires careful monitoring, many people find that taking an oral medication at home is a manageable part of their routine. Patients should discuss specific risk factors for tumor lysis syndrome, potential dose modifications based on health conditions, frequency of blood work during the initial weeks, interactions with current medications, and whether a fixed-duration or indefinite treatment approach is suitable with their doctor.